Bacillus coagulans MZY531 alleviates intestinal mucosal injury in immunosuppressive mice via modulating intestinal barrier, inflammatory response, and gut microbiota

• Published in: Scientific reports 2023-07, Vol.13 (1), p.11181-11181, Article 11181
• Main Authors: Zhao, Zhongwei, Sun, Manqing, Cui, Xinmu, Chen, Jiaxin, Liu, Chunhong, Zhang, Xuewu
• Format: Article
• Language: English
• Subjects: 631/326; 631/601; 692/4020; Animals; Bacillus coagulans; Bacteria; Chemotherapy; Cyclophosphamide; Cyclophosphamide - adverse effects; Endothelial Cells; Gastrointestinal Microbiome; Gram-positive bacteria; Humanities and Social Sciences; Ileum; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunomodulation; Immunosuppression; Immunosuppressive Agents - pharmacology; Inflammation; Interleukin 10; Interleukin 2; Interleukin 4; Intestinal microflora; Intestinal Mucosa; Intestine; Intestines; Jejunum; Mice; Microbiota; Microorganisms; Mucosa; multidisciplinary; MyD88 protein; NF-κB protein; Probiotics; Proteins; Relative abundance; Science; Science (multidisciplinary); Small intestine; Spleen; Thymus gland; TLR4 protein; Toll-like receptors; Villus; Western blotting; Zonula occludens-1 protein; γ-Interferon
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-38379-0

Bacillus coagulans has a potential role in improving intestinal injury. However, the specific mechanism is still unclear. In this study, the protective effect of B. coagulans MZY531 on intestinal mucosa injury in cyclophosphamide (CYP)-induced immunosuppressed mice were investigated. The results indicated that the immune organ (thymus and spleen) indices of B. coagulans MZY531 treatment groups were significantly increased compared to the CYP group. B. coagulans MZY531 administration promotes the expression of immune proteins (IgA, IgE, IgG, and IgM). B. coagulans MZY531 could upregulate the ileum levels of IFN-γ, IL-2, IL-4, and IL-10 in immunosuppressed mice. Moreover, B. coagulans MZY531 restores the villus height and crypt depth of the jejunum and alleviates injury of intestinal endothelial cells caused by CYP. Furthermore, the western blotting results showed that B. coagulans MZY531 ameliorated CYP-induced intestinal mucosal injury and inflammatory via up-regulates the ZO-1 pathway and down-regulates the expression of the TLR4/MyD88/NF-κB pathway. After treatment with B. coagulans MZY531, the relative abundance of Firmicutes phylum was dramatically increased, as well as the genera of Prevotella and Bifidobacterium , and reducing harmful bacteria. These findings suggested that B. coagulans MZY531 has a potential immunomodulatory activity on chemotherapy-induced immunosuppression.